Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barr Gets Go-Ahead For Generic Yasmin

This article was originally published in The Pink Sheet Daily

Executive Summary

ANDA approval comes two months after court ruling on Bayer contraceptive.

You may also be interested in...



Mylan Will Begin Marketing New Generic Oral Contraceptive Portfolio In 2010

Mylan Pharmaceuticals will enter the generic women's health care market with a portfolio of 22 oral contraceptive products acquired through a development and supply agreement with India-based Famy Care

Mylan Will Begin Marketing New Generic Oral Contraceptive Portfolio In 2010

Mylan Pharmaceuticals will enter the generic women's health care market with a portfolio of 22 oral contraceptive products acquired through a development and supply agreement with India-based Famy Care

Court Finds Bayer’s Yasmin Oral Contraceptive Patent Is Invalid

A district court ruling against Bayer’s oral contraceptive patent opens the way for Barr to launch a generic version of Yasmin.

Topics

UsernamePublicRestriction

Register

LL1135975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel